Enninful, Archibald
Zhang, Zhaojun
Klymyshyn, Dmytro
Ingalls, Matthew https://orcid.org/0000-0001-6430-9785
Yang, Mingyu https://orcid.org/0000-0003-0986-3825
Zong, Hailing
Bai, Zhiliang https://orcid.org/0000-0002-3977-3057
Farzad, Negin
Su, Graham
Baysoy, Alev
Nam, Jungmin https://orcid.org/0000-0002-6717-1328
Lu, Yao
Bao, Shuozhen
Deng, Siyan
Zhang, Nancy R. https://orcid.org/0000-0002-0880-5749
Braubach, Oliver
Xu, Mina L. https://orcid.org/0000-0001-9513-245X
Ma, Zongming https://orcid.org/0000-0003-2401-0177
Fan, Rong https://orcid.org/0000-0001-7805-8059
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54CA274509)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA245313)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54CA268083)
U.S. Department of Health & Human Services | National Institutes of Health (UH3CA257393)
U.S. Department of Health & Human Services | National Institutes of Health (RF1MH128876)
U.S. Department of Health & Human Services | National Institutes of Health (U54AG079759)
U.S. Department of Health & Human Services | National Institutes of Health (U54AG076043)
U.S. Department of Health & Human Services | National Institutes of Health (RM1MH132648)
U.S. Department of Health & Human Services | National Institutes of Health (U01CA294514)
Center for Selective C-H Functionalization, National Science Foundation (2245575)
Center for Selective C-H Functionalization, National Science Foundation (2245575)
National Science Foundation (2345215)
National Science Foundation (2245575)
Article History
Received: 5 November 2024
Accepted: 27 October 2025
First Online: 15 January 2026
Competing interests
: R.F. is scientific founder and adviser for IsoPlexis, Singleron Biotechnologies and AtlasXomics. The interests of R.F. were reviewed and managed by Yale University Provost’s Office in accordance with the University’s conflict of interest policies. M.L.X. has served as consultant for Treeline Biosciences, Pure Marrow and Seattle Genetics. The other authors declare no competing interests.